Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceBOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York.
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 MilestonesInitial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 11:15 a.m. PT in San Francisco.
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31, 2024, the company granted equity awards to one new employee, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29, 2024, the company granted equity awards to one new employee, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial ResultsSeven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BOSTON , Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024, the company granted equity awards to six new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (
NASDAQVERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline in the securities class action first filed by the firm.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and iLearningEngines and Encourages Investors to Contact the FirmNEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of WEBTOON Entertainment, Inc. (
NASDAQWBTN), Verve Therapeutics, Inc.
NASDAQ: VERVNASDAQVERV)
(NYSE: DPZNYSEDPZ
, and iLearningEngines, Inc. (NASDAQ: AILENASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Verve To Contact Him Directly To Discuss Their Options
VERV REMINDER – Robbins LLP Urges VERV Investors to Obtain Legal Counsel in Light of the Pending Lead Plaintiff DeadlineSAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics, Inc. (
NASDAQVERV) securities between August 9, 2022 and April 1, 2024. Verve is a “clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines.”
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on September 30, 2024, the company granted equity awards to five new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Verve To Contact Him Directly To Discuss Their Options
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Verve To Contact Him Directly To Discuss Their Options
